Financial Performance - Revenue for Q3 2024 was approximately $35.8 million, a decrease of 5.5% compared to $37.9 million in Q3 2023[2] - Earnings per diluted share were $0.24, down from $0.32 in the same quarter last year, representing a decline of 25%[2] - Net income for Q3 2024 was $5.7 million, compared to $7.9 million in Q3 2023, reflecting a decrease of 27.7%[6] - Total operating expenses for Q3 2024 were approximately $27.8 million, slightly down from $28.0 million in Q3 2023[6] Shareholder Returns - The company returned approximately $11.5 million to shareholders through dividends and stock repurchases during the quarter[3] - The regular quarterly dividend of $0.12 per share was declared, amounting to approximately $2.9 million[3] Contract Value and Debt - Total recurring contract value (TRCV) reached approximately $131.6 million as of September 30, 2024[2] - The company's net indebtedness was approximately $50.2 million as of September 30, 2024[2] Assets and Equity - Total assets increased to $131.8 million from $122.4 million at the end of 2023[7] - Shareholders' equity decreased to $34.6 million from $49.0 million at the end of 2023[7]

United States' approach to nuclear energy innovation. This legislation aims to modernize the NRC's licensing and regulatory practices to be more supportive of marketplace innovation. Within one year of enactment, the NRC must submit a report to Congress detailing specific improvements to nuclear reactor and materials oversight, emphasizing efficiency through risk-informed procedures, advanced technologies, and staff training. Additionally, the ADVANCE Act requires the NRC, in collaboration with the Departme ...

National Research Corporation [NRC] Q1 2024 Earnings Conference Call May 8, 2024 11:00 AM ET Company Participants Linda Stacy - VP, Finance Mark Scudder - ELT Helen Hrdy - CCO Operator Good morning or good afternoon all, and welcome to the National Research Corporation First quarter earnings call. My name is Adam, and I'll be your operator today. [Operator instructions]. I will now hand the floor to Linda Stacy to begin. So, Linda, please go ahead when you're ready. Linda Stacy Thank you, Adam, and welcome, ...

For the quarterly period ended March 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) Delaware 47- ...

Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact:Linda A. Stacy Principal Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER RESULTS LINCOLN, Nebraska (May 7, 2024) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: "NRC continues to be strongly positioned for growth in our expanding markets. O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer inco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State o ...

Financial Data and Key Metrics Changes - Revenue for Q3 2023 increased slightly compared to Q3 2022, ending the quarter with $144.3 million in Total Revenue Contract Value (TRCV) [22] - Operating income decreased by 10% for Q3 2023 compared to Q3 2022, primarily due to growth in certain costs exceeding revenue growth [22] - The effective tax rate in Q3 2023 was 22%, down from 23% in 2022, mainly due to lower state income taxes [4] Business Line Data and Key Metrics Changes - The Human Understanding Program saw an average contract value growth of 13% from existing clients, aligning with previous successful rollouts [15] - The sales force has increased by 19% since the beginning of the year to capitalize on growing demand, contributing to two consecutive quarters of double-digit sales growth compared to the prior year [15] Market Data and Key Metrics Changes - The company is expanding its product offerings to capture a larger total addressable market while gaining market share in the core patient experience market [3] Company Strategy and Development Direction - The company is focused on accelerating revenue growth and expanding margins, with a plan that has shown sequential improvement over the past two quarters [20] - Increased investments in marketing and cybersecurity services are aimed at expanding brand recognition and supporting sales development [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in seeing the results of their efforts reflected in revenue per associate and operating margin in future periods [21] - The company remains well-positioned to execute a range of capital allocation alternatives, including funding for innovation, shareholder dividends, and share repurchases [17] Other Important Information - The company incurred $661,000 in nonrecurring state tax incentive adjustments during the quarter [4] - As of September 30, 2023, the company had approximately $20 million in net debt and $25 million available on the line of credit after funding various expenditures [17] Q&A Session Summary - No specific questions or answers were documented in the provided content, as the call transitioned directly to closing remarks after the prepared comments [5][6][12]

Table of Contents FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Ident ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) Delaware 47- ...